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Inﬂuenza  infection  natural  history  is  often  described  as  a progression  through  four  successive  stages:
Susceptible–Exposed/Latent–Infectious–Removed  (SEIR).  The  duration  of each  stage  determines  the aver-
age  generation  time,  the  time  between  infection  of a  case  and  infection  of  his/her  infector.
Recently,  several  authors  have  justiﬁed  somewhat  arbitrary  choices  in  stage  durations  by  how  close
the  resulting  generation  time  distribution  was  to  viral  excretion  over time  after infection.  Taking  this
reasoning  one  step  further,  we propose  that  the  viral  excretion  proﬁle  over  time  can  be used directly  to
estimate  the  required  parameters  in  an  SEIR  model.  In our  approach,  the  latency  and infectious  period
distributions  are  estimated  by minimizing  the  Kullback–Leibler  divergence  between  the  model-based
generation  time  probability  density  function  and  the  normalized  average  viral  excretion  proﬁle.
Following  this  approach,  we  estimated  that  the latency  and  infectious  period  last  respectively  1.6 and
1.0  days  on average  using  excretion  proﬁles  from  experimental  infections.  Interestingly,  we ﬁnd  that  only
5%  of cases  are  infectious  for  more  than  2.9 days.  We  also discuss  the  consequences  of  these  estimates
for  the  evaluation  of the  efﬁcacy  of control  measures  such  as  isolation  or treatment.  We  estimate  that,
under  a best-case  scenario  where  symptoms  appear  at the  end  of  the  latency  period,  index  cases  must
be  isolated  or  treated  at most  within  16  h  after  symptoms  onset  to  avoid  50%  of  secondary  cases.
This study  provides  the  ﬁrst  estimates  of latency  and  infectious  period  for inﬂuenza  based  directly  on
viral  excretion  data.  It provides  additional  evidence  that  isolation  or  treatment  of cases  would  be  effective
only  if adopted  shortly  after  symptoms  onset,  and  shows  that  four  days  of isolation  may  be enough  to
.avoid  most  transmissions
ntroduction
Inﬂuenza transmission is often studied using the standard
usceptible–Exposed–Infectious–Removed (SEIR) model, where an
nfected individual is ﬁrst latent (or exposed: infected but not infec-
ious), then infectious, before being removed. The latent period
nd infectious period distributions, as well as the contact rate in
he population, must be speciﬁed to obtain quantitative outputs
rom the model. However, somewhat discrepant values have been
sed for the durations of the latent and infectious periods, as illus-
rated in many studies on the 2009 inﬂuenza pandemic (Fraser
Abbreviations: GT, generation time; pdf, probability density function; SEIR,
usceptible–Exposed–Infectious–Removed; sd, standard deviation.
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et al., 2009; Balcan et al., 2009; Colizza et al., 2009; Elveback
et al., 1976; Flahault et al., 2009; Germann et al., 2006; Longini
et al., 2004, 2005; Mills et al., 2004; Tuite et al., 2010; Pedroni et al.,
2010; Baguelin et al., 2010; Yang et al., 2009a; Pourbohloul et al.,
2009; Boni et al., 2009). For example, recent publications used a
range of mean latency period from 0.64 (Fraser et al., 2009) to 3.0
(Pourbohloul et al., 2009) days and from 1.27 (Fraser et al., 2009) to
8.0 (Pourbohloul et al., 2009) days for the mean infectious period
(see Fig. 1). For most studies (7 out of 9), these values were however
not based on direct estimation from data. Indeed, detailed stud-
ies of inﬂuenza transmission are scarce; direct observation of the
duration of latency or infectious period is impossible and nontriv-
ial statistical analyses are necessary to estimate the time course of
infectivity from observed chains of transmission. Some examples
include the analysis of transmission within households or using
Open access under CC BY-NC-ND license.epidemic curves (Fraser et al., 2009; Cauchemez et al., 2004; Boelle
et al., 2011).
In  view of these issues, alternative sources of information
regarding the required parameters would be of interest. A
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Fig. 1. Comparison of several latencies and infectious periods found in the literature (Fraser et al., 2009; Balcan et al., 2009; Flahault et al., 2009; Tuite et al., 2010; Pedroni
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ceptible individual can be made equal in both models, therefore
leading to the same transmission dynamics.t al., 2010; Baguelin et al., 2010; Yang et al., 2009a; Pourbohloul et al., 2009; Bon
ines show, when available, the symmetric 95% probability interval. The studies abov
elow  the gray line posit the values, in general to match a certain mean generation
atural candidate is the proﬁle of viral excretion following infec-
ion, measured in experimental infections with known time of
nfection (Carrat et al., 2008). Indeed, viral excretion forms the bio-
ogical basis of transmission. Importantly, proﬁles of viral excretion
ave been put forward in several recent models to support par-
icular model parameterizations. For example, Mills et al. (2004)
eported that their choice of parameters made the probability of
eing infectious “comparable with the relative amount of viral
hedding from human volunteer studies”; Ferguson et al. (2005)
stimated a proﬁle of infectiousness over time “remarkably consis-
ent with viral shedding data from experimental infection studies”,
nd Chao et al. (2010), assumed that “the individual’s infectiousness
was) proportional to the log of the daily viral titers”.
Taking this reasoning one step further, it is natural to propose
hat viral titers could be used as a primary source for SEIR parameter
stimation. This was already suggested in a review of human exper-
mental inﬂuenza infections (Carrat et al., 2008), where an average
eneration time was calculated from viral titers proﬁles over time.
owever, as of today, no method has been described to estimate
he latent and infectious periods of the standard SEIR model based
n viral excretion data. Therefore, in this article, we  ﬁrst show how
hese two components of the standard SEIR model may  be related
o viral excretion proﬁles. We  show that this relationship can be
xpressed in terms of the generation time distribution (GT, time
etween infection of a case and infection of his/her infector), which
s a key parameter in epidemic models. The latency and infectious
eriod for inﬂuenza are then estimated by equating the SEIR dis-
ribution of the generation time to the viral excretion proﬁle using
xperimental data. Using these estimates, and considering the best
ase scenario where the appearance of symptoms coincides with
he end of the latent period, we compute the proportion of sec-
ndary infections avoided by isolation or effective treatment at a
ertain time after symptoms onset. We  ﬁnally discuss our results
ith respect to other published values of latency and infectious
eriod.
inking the generation time distribution in the standard
EIR  model to viral excretionutline
We  ﬁrst describe two models of inﬂuenza transmission: the
rst one is the standard SEIR model; the second one is a new., 2009), and the corresponding generation time. The dots show the mean and the
 gray line estimate the mean latency and the mean infectious period, whereas those
formulation  proposed to link viral excretion with transmission. The
natural history of inﬂuenza described by these two models will be
different at the individual level, as the ﬁrst assumes a constant haz-
ard of transmission during a deﬁned infectious period, while the
other proposes time dependent hazard of transmission related to
viral excretion. However, we will show that both models can lead to
the same description at the population level, as illustrated in Fig. 2:
in other words, the force of infection exerted at each time on a sus-Fig. 2. Schematic parallel between infectiousness after infection in the Standard
SEIR  model and the viral excretion model, at the individual and population levels.
See main text for explanations on notations. xk designates the realization of a random
variable x in individual k.
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Matching these two models thus allows estimating parameters
f the standard SEIR model from viral excretion data. The resulting
EIR model will be equivalent, at the population level, to the viral
xcretion model (Fig. 2).
eneration time in the standard SEIR model
In the standard SEIR model, susceptible individuals become
nfected through contact with an infectious case. After infection,
 case is latent (i.e. in the E stage) for a random duration L then
nfectious for a random period J and is eventually removed. The
robability density functions (pdf) of L and J are denoted fL and fJ. For
ach case, his/her rate of contact leading to disease transmission is
ssumed to be non-zero and constant during the infectious period,
ith random value ˇ. Following Svensson (2007), we assume that
, J, and  ˇ are independent. In this description, secondary infections
aused by a case occur according to a time inhomogeneous Poisson
rocess with intensity ˇ1{L≤t≤L+J}, where 1A denotes the indicator
unction deﬁned by 1A = 1 if A is true and 1A = 0 otherwise.
The probability density function of the generation time is
Svensson, 2007)
SEIR(t) = (fL ∗ gJ)(t) (1)
here  ∗ stands for the convolution operator, gJ(t) = (1 − FJ(t))/E[J],
ith FJ the cumulative density function of J and E[J] the expecta-
ion of J. In this model,  SEIR(t)E[J] equals the percentage of cases
ho are still infectious at time t after infection, thereby linking the
infectious proﬁle” to the generation time distribution. We  assume
hat the distributions of L and J are fully characterized by a vector
f parameters , so that the generation time pdf is  SEIR(t, ).
eneration time in the viral excretion model
We describe here a transmission model based on individual viral
xcretion where the generation time distribution would match
he (suitably normalized) average viral excretion proﬁle over time.
 common description of transmission models is that infected
ndividuals make infectious contacts in time according to a time
nhomogeneous Poisson process with intensity k(t), where  is a
andom amount of infectivity, and k(t) the probability density of a
random) positive measure (Svensson, 2007). We  let this intensity
e proportional to V(t), the (random) viral excretion at time t after
nfection (i.e. k(t) = ωV(t), where ω is a positive random number).
his particular formulation would arise, for example, if contacts
ccurred according to a homogeneous Poisson process in time, with
ransmissibility per contact proportional to viral excretion at that
ime.
Importantly, and irrespective of interpretation, the (backwards)
eneration time distribution associated with this transmission pro-
ess is the normalized average viral excretion proﬁle
V (t) =
E[V(t)]∫ +∞
u=0 E[V(u)]du
,
n  exact agreement with the empirically derived result by Carrat
t al. (2008).
This  review of experimental inﬂuenza infection studies pro-
ided the average proﬁles of viral excretion after infection
easured in 12 studies where human volunteers were experimen-
ally challenged with seasonal AH1N1 or AH3N2 inﬂuenza virus.
e used the weighted mean of these curves, summarizing viralxcretion in 157 individuals.
The  discrete (daily) estimate of the generation time probability
ensity function obtained using this average viral excretion proﬁle
s denoted ̂V .4 (2012) 132–138
Identical dynamics in SEIR and viral excretion model with
identical generation time distribution and R0
Consider an epidemic model in which individuals are classiﬁed
as susceptible or infected. Susceptible individuals can be infected
through contact with infected cases. The probability of transmis-
sion given a contact depends on the infectivity of the infected case
at time of contact. The dynamics of the deterministic model in a
population of size N, in terms of the incidence H and the number
of susceptibles S, is governed by the following renewal equations
(see for example Fraser, 2007):
dS
dt
=  −H(t)
H(t) = S(t)
N
∫ +∞
=0
R0 ()H(t − )d
where R0 is the basic reproduction number (average number of
secondary cases that an infected individual introduced in a fully
susceptible population would infect) and   is the probability
density function of the generation time (average time between
infection of a case and infection of his/her infector).
From those equations, it is clear that two  epidemics in the same
population, with the same reproduction number, the same gener-
ation time distribution, and the same initial conditions, will have
exactly the same dynamics of incidence and number of suscepti-
bles.
Therefore, this provides a formal link between the two  models
presented above. If the standard SEIR model is calibrated so that
its generation time distribution matches that of the viral excretion
model, then the dynamics of both models will be exactly the same,
starting from the same initial conditions.
Estimating the inﬂuenza latency and infectious period
distributions from viral excretion data
Parametric deconvolution of the generation time distribution
The  vector  of parameters specifying the distributions
of the latent and infectious period in the standard SEIR
model was  estimated by minimizing the Kullback–Leibler
(KL) divergence D() between ̂V and  SEIR, where D() =∑T
d=0̂V (d)log(̂V (d)/(d, )) (Kullback, 1959). In this expression,
T  is the number of days with detectable excretion and ϕ(d, ) =∫ d+1/2
d−1/2 SEIR(u, )du is the discretized SEIR model-based generation
time pdf, integrated over a time step of one day.
Both the latency L and infectious period J are assumed to follow
shifted Weibull distributions, with parameters  = (sL, aL, bL, sJ, aJ,
bJ) and respective pdf:
fX (t) =
(
aX
bX
)  (
t − sX
bX
)aX−1
e−(t−sX/bX )
aX 1{t≥sX } (2)
for  X = L or J. In that formulation, sX, aX, bX are respectively the shift,
shape and scale parameters of the Weibull distribution.
The integrals were numerically estimated using the
Gauss–Kronrod quadrature with 61 Kronrod points (Kronrod,
1965) and D minimized using a conjugate gradient algorithm
(Bonnans et al., 2003). For all numeric aspects, custom routines
were coded using the C language and the GNU Scientiﬁc Library.
Conﬁdence  intervalsTo  estimate the variability of parameter estimates, we used a
leave one out (jackknife) approach (Shao, 2003): we obtained 12
different average viral excretion proﬁles by systematically omitting
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ne of the 12 studies (and thereby removing one of the 12 average
roﬁles of viral excretion) considered by Carrat et al. (2008). Jack-
nife estimates of the standard deviations of estimated parameters
ere then obtained from the repeated estimations.
alidation
We numerically checked the identiﬁability of model parameters.
First, the criterion D() was calculated over a grid of plausible
arameter values to investigate the uniqueness of the minimum.
e considered values of the average infectious period between
.25 and 5.75 days (step 0.25) and values of the average latency
eriod between 0.25 and 3.25 days (step 0.25). For both distribu-
ions we investigated coefﬁcients of variation (ratio of the standard
eviation over the mean) between 0.25 and 5 (step 0.25)
Then,  the shifted-Weibull distributions for L and J (see formula
2)) were replaced with shifted-Gamma distributions, and the esti-
ates obtained under both assumptions were compared.
Finally, we  applied our estimation procedure to generation time
istributions obtained from known latency and infectious periods.
wo sets of distributions for L and J were taken from the literature:
hose proposed by Elveback et al. (1976) and Longini et al. (2005)
espectively. In each case, the GT distribution was ﬁrst calculated
sing formula (1); then the deconvolution procedure was applied,
nd the relative error of estimation in the mean and standard devi-
tion of L and J was computed.
redicting  the effectiveness of isolation or treatment
Isolation and treatment of symptomatic cases are often con-
idered in order to bring an epidemic under control. Such control
easures can only be introduced once cases have been detected,
hus after symptoms onset. Their effectiveness can be assessed by
uantifying, for each case, the proportion of the overall infectivity
hat is avoided thanks to the control measures.
Assuming that infectivity is proportional to viral excretion, this
equires the knowledge of individual viral excretion proﬁles and
imes of symptoms onset, data which are scarce, and which we did
ot have access to.
However,  studies using a SEIR formulation commonly assume
hat for inﬂuenza, latency and incubation period coincide (Fraser
t al., 2009; Balcan et al., 2009; Yang et al., 2009a; Boni et al., 2009;
erguson et al., 2005; Carrat et al., 2006), so that symptoms onset
orresponds to the beginning of the infectious period. Making such
n assumption allows linking the dynamics of infections predicted
y the model with the observed dynamics of symptomatic cases.
ig. 3. (A) Normalized average daily viral excretion after experimental inﬂuenza infection
robability density function using a standard SEIR model (gray bars). (B) Estimated distri4 (2012) 132–138 135
Other studies (Pourbohloul et al., 2009) assume that symptoms
appear sometime after the beginning of the infectious period.
From  a control measure perspective, this second scenario is
worse as it allows an infectious asymptomatic stage, where indi-
viduals are infectious but cannot be detected. Here, we consider
the best-case scenario where symptoms appear at the end of the
latency period. Assessing the effectiveness of isolation or treatment
of cases under this scenario is quite straightforward within the SEIR
framework.
Using the estimated infectious period distribution, we  com-
puted the proportion of secondary infections which could be
avoided if all symptomatic cases were isolated (or treated with a
treatment reducing infectivity by 100%) at time 	 after onset of
symptoms (assumed equal to the start of infectious period), and
for a duration .
We  assumed that an infected case effectively isolated or treated
at time 	 after symptoms onset and for a duration  would cause
 ˇ × (J1J≤	 + max(	, J − )1J>	) secondary cases, leading to a pro-
portion ε(	, ) =
∫ +∞
j=	 min(j − 	, )fJ(j)dj/
∫ +∞
j=0 jfJ(j)dj of avoided
secondary  infections. In the case of treatment, the parameter 	 can
be seen as incorporating both the time between symptoms onset
and treatment and a possible delay after treatment before reduction
of infectivity.
Numerical results
The  best ﬁt between the discretized SEIR generation time pdf
and the normalized average daily viral excretion proﬁle is shown
in Fig. 3A. The corresponding latency distribution has average
1.63 ± 0.06 days and standard deviation (sd) 0.26 ± 0.08 days and
the infectious period distribution average 0.99 ± 0.25 days and sd
0.96 ± 0.15 days, as shown in Fig. 3B and C. The infectious period is
typically short, with 95% (respectively 99%) of cases having an infec-
tious period shorter than 2.90 ± 0.55 days (respectively 4.41 ± 0.63
days).
Numerical explorations did not reveal identiﬁability problems.
A thorough exploration of the parameter space showed a unique
minimum (see Fig. 4 for the mean values). Using shifted Gamma dis-
tributions for L and J led to very similar results: the average latency
was 1.7 days (sd 0.3 day) and the average infectious period was  1.0
days (sd 0.9 day).
Last,  the relative errors between the original and reestimated
parameters means in the Elveback (Elveback et al., 1976) and in the
Longini (Longini et al., 2005) distributions were less than 2%.
Fig.  5 shows the proportion of secondary infections which could
be avoided by isolating or treating cases after symptoms onset,
depending on the duration of isolation or treatment. To reduce by
 (hatched bars, data from Carrat et al., 2008), and ﬁtted discretized generation time
bution for the latency L. (C) Estimated distribution for the infectious period J.
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aig. 4. Minimum value of the Kullback–Leibler (KL) divergence according to the
verage latency (x axis) and infectious period (y axis). The dot indicates the estimated
inimum. The KL divergence at this point has a value of 0.0037.
0% the number of secondary cases, a case should be isolated or
reated at most within 16 h after symptoms onset. If cases were
solated or treated 2 days after symptoms onset, the proportion of
econdary cases avoided would be only 12%.
iscussion
Viral excretion has been put forward to qualitatively support the
hoice of parameter values in transmission models in several recent
ajor publications regarding inﬂuenza. However, as of now, viral
xcretion has not been used for obtaining more quantitative esti-
ates. Here, we  proposed that viral excretion proﬁle can be linked
o the generation time distribution in the standard SEIR model, and
e estimated parameters under this assumption.
Using time proﬁles of viral excretion in subjects experimentally
nfected with inﬂuenza, we have estimated that the mean latency
nd infectious period for inﬂuenza are 1.6 (95%CI 1.5–1.7) and 1.0
ays (95%CI 0.5–1.7). In particular, we found that 95% of cases were
nfectious for less than 2.9 days. This is remarkably consistent with
ecent results obtained by Donnelly et al. (2011) who  estimated,
ith independent data and a totally different approach, that only
% of transmission events took place >3 days after the onset of
ig. 5. (A) Proportion of avoided secondary infections according to time and duration of iso
ssuming permanent isolation.4 (2012) 132–138
clinical  symptoms with H1N1 2009 infection. The short infectious
period makes interventions aiming at reducing transmission highly
dependent on the time of initiation after symptoms onset.
On  the occasion of the 2009 A/H1N1 pandemic, estimates of the
generation time from ﬁeld data were very consistent, with a mean
value of 3 days (Boelle et al., 2011). However, in models of inﬂuenza
transmission using a standard SEIR formulation for the natural his-
tory, the average generation time was not always in accordance
with this value (see Fig. 1). Moreover, in most models, the mean
latency and infectious period durations were somewhat arbitrarily
chosen to match a certain average generation time rather than esti-
mated. Therefore, to compare our results with other studies, it is fair
to distinguish between the studies where the parameters were esti-
mated from data and those where “guesstimates” were used, and
to gauge how realistic the corresponding generation times were.
Fig.  1 shows that the average duration of the latency period
found in our study compares with that generally used for modeling
inﬂuenza, although our distribution of the latency period is nar-
rower than most distributions used in the literature. This might be
an effect of not using an exponential distribution, unlike most other
studies. On the other hand, our estimate of the average duration of
the infectious period is lower than most values used in models.
However, our distribution of the infectious period compares with
that in Baguelin et al. (2010), the only other study where a realistic
generation time distribution was  used and latency and infectious
period were estimated: their estimated average latency period was
1.40 days (versus 0.99 in our study), with a 95% probability interval
of [0.19–3.90] (versus [0.04–3.55] in our study).
It is difﬁcult to assess to what extent the viral excretion proﬁle
after experimental infection is similar to that after natural infec-
tion, since measuring viral excretion early after natural infection
is challenging. However, it is reassuring that several studies, which
analyzed transmission chains in closed settings such as households,
have estimated generation time distributions which are consistent
with the average viral excretion proﬁle after experimental infec-
tion (Fraser et al., 2009; Yang et al., 2009a; Ferguson et al., 2005;
Cauchemez et al., 2009; Ghani et al., 2009; White et al., 2009; Lessler
et al., 2009; Hahne et al., 2009; McBryde et al., 2009; France et al.,
2010; Suess et al., 2010; Leung et al., 2010).
One may  also object that our results depend on the scale over
which viral excretion is expressed. For example, in Mills et al. (2004)
and Chao et al. (2010), the viral excretion data is on the log-scale
to match the GT distribution used; on the contrary, Ferguson et al.
(2005) compared infectivity proﬁles with viral excretion on the nat-
ural scale. Quantitatively, we found that the difference was not
negligible: the mean GT was  3.5 days (Jackknife 95% CI 3.2–3.9
lation. (B) Proportion of avoided secondary infections according to time of isolation,
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ays) using the normalized viral excretion on the log scale, but
nly 2.6 days (Jackknife 95% CI 2.4–2.8 days) using the natural scale.
lthough the former option leads to a generation interval in agree-
ent with data reported in a recent study where the average GT was
.6 days (95% CI 2.9–4.3 days) (Cowling et al., 2009), most estimates
eported during the A/H1N1 (2009) pandemic (Fraser et al., 2009;
ang et al., 2009a; Cauchemez et al., 2009; Ghani et al., 2009; White
t al., 2009; Lessler et al., 2009; Hahne et al., 2009; McBryde et al.,
009; France et al., 2010; Suess et al., 2010; Leung et al., 2010) and
easonal inﬂuenza (Cauchemez et al., 2004; Ferguson et al., 2005)
upport a shorter generation time, so that the choice of the natural
cale for viral excretion appears to better match epidemiological
vidence.
The infectious period distribution provides crucial information
n the effectiveness of control measures depending on their timing
nd duration. Based on our new estimate of the infectious period
istribution, and under the optimistic but commonly adopted sce-
ario where symptoms onset coincides with the beginning of the
nfectious period, in order to achieve a 50% reduction in the num-
er of secondary cases, it is necessary to isolate or treat index
ases at most within 16 h after symptoms onset. If cases are iso-
ated or treated as late as 2 days after symptoms onset, only 12%
f secondary cases can be avoided. These results were obtained by
ssuming that all cases became symptomatic at the start of their
nfectious period.
A  more realistic assumption is that the infectious period starts
efore the onset of symptoms. For instance, Lessler et al. (2009)
ound a median incubation period of 1.4 days, which is shorter
han our median latency period of 1.63 days. If the infectious period
ndeed starts before the onset of symptoms, isolation or treatment
f index cases would be even less effective than what we found.
ccounting for asymptomatic infections would also lead to more
ramatic results. Our results are in line with those of other studies
Yang et al., 2009b; Halloran et al., 2007), which found no effec-
iveness of treating index cases with antivirals within the two  days
ollowing symptoms onset. As a comparison, assuming an infec-
ious period distributed as in Yang et al. (2009a) with a higher
verage (5 days versus 1 day for us), 60% of secondary cases would
e avoided by isolating or treating cases within 2 days after symp-
oms onset.
Our  study provides the ﬁrst estimates of inﬂuenza natural his-
ory parameters based on viral excretion data, which supports a
hort infectious period lasting one day on average. This result is
dditional evidence that isolation or treatment of cases would be
fﬁcient only if initiated within the few hours after symptoms
nset. Therefore, it is very unlikely that an infected individual can
e isolated or treated early enough after his symptoms. A more
fﬁcient control strategy would consist in isolating or treating close
ontacts of symptomatic individuals. Those contacts, although they
re likely to have already been infected, might not be infectious yet.
ence isolating or treating them might effectively prevent further
ransmission.
Our method could be applied to estimate the durations of
atency and infectious period in standard SEIR models for any
athogen for which viral excretion proﬁles or, more generally,
eneration time distributions, are available. In particular, different
stimates could be obtained for the latency and infectious period
ccording to the inﬂuenza subtype. It would also be interesting to
ssess how the latency and infectious period are modiﬁed under
ntiviral treatment by applying our method to viral excretion pro-
les measured in infected individuals under antiviral treatment.
oreover, here, we assumed that the distribution of the generationime was given by the average proﬁle of viral excretion after infec-
ion. We  neglected behavioral and environmental components of
he infectiousness (Grassly and Fraser, 2008), which could affect the
eneration time distribution if they vary over time. If reliable data4 (2012) 132–138 137
on  the dynamics of contacts after infection were available, these
data could, together with data on viral excretion proﬁles, lead to
a more accurate description of the generation time distribution.
Our method could then be applied to estimate the corresponding
durations of latency and infectious periods.
Finally, a natural continuation of this work, which would require
individual data on viral excretion proﬁles after infection, would be
to compare the stochastic SEIR model, calibrated using our method,
to the stochastic model in which each individual is assumed infec-
tious proportionally to his/her viral load. While, as we have shown,
the dynamics of the deterministic models are the same, the dynam-
ics of the stochastic versions should be different. In particular, it
would be interesting to compare the effect of control measures in
both frameworks.
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